[Prognostic factors in lymph node negative breast cancer].
Kleeberg
U R
UR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D015999:Multivariate Analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015842:Serine Proteinase Inhibitors / Q000032:analysis*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D014568:Urokinase-Type Plasminogen Activator; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate